BIOMAT Database Logo BIOMAT Database Logo

Tenofovir Plasma Trough Concentrations in People Living with HIV Treated with Tenofovir Disoproxyl Fumarate: Antiretroviral Class or Individual Drug Effect? 2023

Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens.
December 2021, AIDS (London, England),
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
November 2021, Clinical drug investigation,
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.
March 2017, The Journal of infectious diseases,
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Higher plasma drug levels in elderly people living with HIV treated with darunavir.
January 2021, PloS one,
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
July 2020, AIDS (London, England),
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
October 2022, Journal of acquired immune deficiency syndromes (1999),
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate.
January 2022, Journal of the International Association of Providers of AIDS Care,
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience.
December 2023, International journal of STD & AIDS,
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Correction: Higher plasma drug levels in elderly people living with HIV treated with darunavir.
January 2021, PloS one,
Dario Cattaneo, and Stefano Bonora, and Paola Meraviglia, and Stefania Vimercati, and Spinello Antinori, and Cristina Gervasoni
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.
May 2003, AIDS (London, England),
Copied contents to your clipboard!